Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Fausto PetrelliAntonio GhidiniRebecca PedersiniMary CabidduKaren BorgonovoMaria Chiara ParatiMara GhilardiVito AmorosoAlfredo BerrutiSandro BarniPublished in: Breast cancer research and treatment (2019)
Based on PFS and ORR results of this indirect meta-analysis, palbociclib, ribociclib, and abemaciclib are equally effective in either first- or second-line therapy for advanced ER + BC. They, however, ported different toxicity profiles.